Vaginal micronized progesterone capsules for the prevention of miscarriage and preterm birth: a review of the clinical evidence

CADTH
Record ID 32015000288
English
Authors' recomendations: Limited evidence suggests that the risks of preterm birth < 37 weeks or < 34 weeks may be lower with micronized progesterone capsules compared with placebo or no treatment. However, there were inconsistencies with respect to statistical significance and results need to be interpreted with caution. One study suggested that the risk of miscarriage in women with singleton pregnancy who had a history of preterm birth was similar for treatment with either micronized progesterone capsule or placebo. There was no statistically significant difference in risk of neonatal complications between micronized progesterone capsule and placebo. Information on long term efficacy and safety of micronized progesterone capsules are lacking.
Details
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Administration, Intravaginal
  • Premature Birth
  • Abortion, Spontaneous
  • Pregnancy
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: publications@cadth.ca
Contact Email: publications@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.